Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component

European Radiology

Volumn 21, Issue 2, 2011, Pages 256-264

  Veit Haibach, Patrick ^a,b   Schiesser, Marc ^a   Soyka, Jan ^a   Strobel, Klaus ^a   Schaefer, Niklaus G ^a   Hesselmann, Rolf ^a   Clavien, P A ^a   Hany, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LUZERNER KANTONSSPITAL   (Switzerland)

Author keywords

DOPA; Multi phase CT; Neuroendocrine tumors; PET CT; Therapeutic impact

Indexed keywords

CONTRAST MEDIUM; DOPA;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MCNEMAR TEST; METASTASIS; NEUROENDOCRINE TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; IOHEXOL; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 79951904863     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-010-1930-4     Document Type: Article

References (34)

1. C Lepage AM Bouvier JM Phelip C Hatem C Vernet J Faivre 2004 Incidence and management of malignant digestive endocrine tumours in a well defined French population Gut 53 549 553 1:STN:280:DC%2BD2c7isFCjuw%3D%3D 10.1136/gut.2003. 026401 15016750 (Pubitemid 38372980)
2. IM Modlin M Kidd I Latich MN Zikusoka MD Shapiro 2005 Current status of gastrointestinal carcinoids Gastroenterology 128 1717 1751 10.1053/j.gastro. 2005.03.038 15887161 (Pubitemid 40692562)
3. BG Taal O Visser 2004 Epidemiology of neuroendocrine tumours Neuroendocrinology 80 Suppl 1 3 7 10.1159/000080731 1:CAS:528: DC%2BD2cXotlahtL8%3D 10.1159/000080731 15477707 (Pubitemid 39382359)
4. JC Yao M Hassan A Phan, et al. 2008 One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States J Clin Oncol 26 3063 3072 10.1200/JCO.2007.15.4377 10.1200/JCO.2007.15.4377 18565894
5. F Gibril JC Reynolds JL Doppman, et al. 1996 Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study Ann Intern Med 125 26 34 1:STN:280:DyaK283ksFSkug%3D%3D 8644985
6. S Hoegerle C Altehoefer N Ghanem I Brink E Moser E Nitzsche 2001 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels Eur J Nucl Med 28 64 71 1:CAS:528:DC%2BD3cXovFyjt7w%3D 10.1007/s002590000404 11202454 (Pubitemid 32120808)
7. PL Jager KP Koopmans EG de Vries 2006 Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy Ned Tijdschr Geneeskd 150 2401 2403 1:STN:280: DC%2BD28nmsFakuw%3D%3D 17103497 author reply 2403 (Pubitemid 44702116)
8. Y Krausz Z Keidar I Kogan, et al. 2003 SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours Clin Endocrinol (Oxf) 59 565 573 1885[pii] 10.1046/j.1365-2265.2003.01885.x (Pubitemid 37357615)
9. R Lebtahi G Cadiot M Mignon D Le Guludec 1998 Somatostatin receptor scintigraphy: a first-line imaging modality for gastroenteropancreatic neuroendocrine tumors Gastroenterology 115 1025 1027 1:STN:280: DyaK1cvls1ynsA%3D%3D 10.1016/S0016-5085(98)70283-5 9786730
10. Ambrosini V, Campana D, Bodei L, et al 68 Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. doi: 10.2967/jnumed.109.071712
11. KP Koopmans EG de Vries IP Kema, et al. 2006 Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study Lancet Oncol 7 728 734 10.1016/S1470-204570801-4 1:CAS:528:DC%2BD28Xptlyrsr4%3D 10.1016/S1470-2045(06)70801-4 16945767 (Pubitemid 44283659)
12. KP Koopmans OC Neels IP Kema, et al. 2008 Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography J Clin Oncol 26 1489 1495 10.1200/JCO.2007.15.1126 10.1200/JCO.2007.15.1126 18349401
13. G Antoch J Kanja S Bauer, et al. 2004 Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of Imatinib (STI571) therapy in patients with gastrointestinal stromal tumors J Nucl Med 45 357 65 1:CAS:528:DC%2BD2cXivVCjur0%3D 15001674 (Pubitemid 47618607)
14. G Antoch J Stattaus AT Nemat, et al. 2003 Non-small cell lung cancer: dual-modality PET/CT in preoperative staging Radiology 229 526 533 10.1148/radiol.2292021598 14512512 (Pubitemid 37310842)
15. T Beyer DW Townsend TM Blodgett 2002 Dual-modality PET/CT tomography for clinical oncology Q J Nucl Med 46 24 34 1:STN:280:DC%2BD38zjtVSisA%3D%3D 12072843 (Pubitemid 34808736)
16. P Veit-Haibach CA Kuehle T Beyer, et al. 2006 Whole-body PET/CT-colonography: diagnostic accuracy of a new staging concept in patients with colorectal cancer JAMA 296 2590 2600 1:CAS:528:DC%2BD28Xht12ltLfM 10.1001/jama.296.21.2590 17148724 (Pubitemid 44903862)
17. Valk PE, Bailey DL, Townsend DW, Maisey MN (2003) Positron emission tomography: basic science and clinical practice. Springer, London
18. H Ahlstrom B Eriksson M Bergstrom P Bjurling B Langstrom K Oberg 1995 Pancreatic neuroendocrine tumors: diagnosis with PET Radiology 195 333 337 1:STN:280:DyaK2M3ktFOjsA%3D%3D 7724749
19. M Beheshti S Pocher R Vali, et al. 2009 The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT Eur Radiol 19 1425 1434 10.1007/s00330-008-1280-7 10.1007/s00330-008-1280-7 19156423
20. S Hoegerle C Altehoefer N Ghanem, et al. 2001 Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors Radiology 220 373 380 1:STN:280:DC%2BD3MvjtFWksA%3D%3D 11477239 (Pubitemid 32667172)
21. S Hoegerle N Ghanem C Altehoefer, et al. 2003 18F-DOPA positron emission tomography for the detection of glomus tumours Eur J Nucl Med Mol Imaging 30 689 694 10.1007/s00259-003-1115-3 1:CAS:528:DC%2BD3sXjsF2ksb0%3D 10.1007/s00259-003-1115-3 12618904 (Pubitemid 36612951)
22. Koopmans PJ, Barth M, Norris DG Layer-specific BOLD activation in human V1. Hum Brain Mapp. doi: 10.1002/hbm.20936
23. C Nanni S Fanti D Rubello 2007 18F-DOPA PET and PET/CT J Nucl Med 48 1577 1579 10.2967/jnumed.107.041947 10.2967/jnumed.107.041947 17909255 (Pubitemid 47572702)
24. Ambrosini V, Nanni C, Zompatori M, et al Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 37:722-727. doi: 10.1007/s00259-009-1349-9
25. A Becherer M Szabo G Karanikas, et al. 2004 Imaging of advanced neuroendocrine tumors with F-FDOPA PET J Nucl Med 45 1161 1167 1:CAS:528:DC%2BD2cXnsFygsLk%3D 15235062 (Pubitemid 47611661)
26. V Ambrosini P Tomassetti D Rubello, et al. 2007 Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours Nucl Med Commun 28 473 477 10.1097/MNM.0b013e328182d606 10.1097/MNM.0b013e328182d606 17460538 (Pubitemid 46684197)
27. Putzer D, Gabriel M, Kendler D, et al Comparison of Ga-DOTA-Tyr- octreotide and F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 54:68-75.
28. A Haug CJ Auernhammer B Wangler, et al. 2009 Intraindividual comparison of 68 Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours Eur J Nucl Med Mol Imaging 36 765 770 10.1007/s00259-008-1030-8 1:CAS:528:DC%2BD1MXkt1yms70%3D 10.1007/s00259-008- 1030-8 19137293
29. M Gabriel A Oberauer G Dobrozemsky, et al. 2009 68 Ga-DOTA-Tyr3- octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy J Nucl Med 50 1427 1434 10.2967/jnumed.108.053421 1:CAS:528:DC%2BD1MXhtFOrtbrN 10.2967/jnumed.108.053421 19690033
30. F Montravers K Kerrou V Nataf, et al. 2009 Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors J Clin Endocrinol Metab 94 1295 1301 10.1210/jc.2008-1349 1:CAS:528: DC%2BD1MXksFaitbs%3D 10.1210/jc.2008-1349 19141589
31. V Ambrosini D Campana L Bodei, et al. 2010 68 Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors J Nucl Med 51 669 673 10.2967/jnumed.109.071712 10.2967/jnumed.109.071712 20395323
32. M Schiesser P Veit-Haibach MK Muller, et al. 2010 Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours Br J Surg 97 691 697 10.1002/bjs.6937 1:STN:280:DC%2BC3c3mt1GhsA%3D%3D 10.1002/bjs.6937 20225244
33. SM Sjoblom 1988 Clinical presentation and prognosis of gastrointestinal carcinoid tumours Scand J Gastroenterol 23 779 787 1:STN:280: DyaL1M7ksF2ruw%3D%3D 10.3109/00365528809090760 3227292
34. HJ Timmers M Hadi JA Carrasquillo, et al. 2007 The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma J Nucl Med 48 1599 1606 10.2967/jnumed.107.042721 1:CAS:528:DC%2BD2sXht1GlurjL 10.2967/jnumed.107.042721 17873132 (Pubitemid 47572706)